Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA.

AIDS. 1998 May 7;12(7):F51-8.

PMID:
9619798
3.

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.

Kaul DR, Cinti SK, Carver PL, Kazanjian PH.

Pharmacotherapy. 1999 Mar;19(3):281-98. Review.

PMID:
10221367
4.

Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.

Graham NM.

J Acquir Immune Defic Syndr. 2000 Oct 1;25 Suppl 1:S4-11. Review.

PMID:
11126425
5.

Management of protease inhibitor-associated hyperlipidemia.

Penzak SR, Chuck SK.

Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.

PMID:
14727985
6.

The choice of HIV protease inhibitor: indinavir is currently the best option.

[No authors listed]

Prescrire Int. 1999 Apr;8(40):55-60. Review.

PMID:
10848067
7.

Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.

Holstein A, Plaschke A, Egberts EH.

Exp Clin Endocrinol Diabetes. 2001;109(8):389-92. Review.

PMID:
11748485
9.

HIV-1 protease inhibitors.

Deeks SG, Volberding PA.

AIDS Clin Rev. 1997-1998:145-85. Review. No abstract available.

PMID:
9305448
10.

[Cardiovascular risk factors associated with antiretroviral therapy].

Pérez-Camacho I, Camacho A, Torre-Cisneros J, Rivero A.

Enferm Infecc Microbiol Clin. 2009 Sep;27 Suppl 1:24-32. doi: 10.1016/S0213-005X(09)73442-1. Review. Spanish.

PMID:
20172412
11.

Nelfinavir. A review of its therapeutic efficacy in HIV infection.

Jarvis B, Faulds D.

Drugs. 1998 Jul;56(1):147-67. Review.

PMID:
9664204
12.

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Carr A, Samaras K, Chisholm DJ, Cooper DA.

Lancet. 1998 Jun 20;351(9119):1881-3. Review.

PMID:
9652687
13.

[Clinical application of HIV protease inhibitors].

Chiba N, Shintani M, Ueno T, Hayashi H.

Tanpakushitsu Kakusan Koso. 1998 May;43(6):744-51. Review. Japanese. No abstract available.

PMID:
9612068
14.

[HIV protease inhibitors].

Rubio R, Romeu J, Viciana P, Redondo C.

Enferm Infecc Microbiol Clin. 1996 Oct;14 Suppl 1:10-4. Review. Spanish. No abstract available.

PMID:
9053020
15.

Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Behrens GM, Stoll M, Schmidt RE.

Drug Saf. 2000 Jul;23(1):57-76. Review.

PMID:
10915032
16.

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.

Chen D, Misra A, Garg A.

J Clin Endocrinol Metab. 2002 Nov;87(11):4845-56. Review.

PMID:
12414837
17.

Alteration in pancreatic islet function in human immunodeficiency virus.

Haugaard SB.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):697-708. doi: 10.1016/j.ecl.2014.06.004. Review.

PMID:
25169562
18.

[Blood lipid abnormalities during treatment with protease inhibitors].

Vergès B, Petit JM.

Presse Med. 2001 May 19;30(18):911-4. Review. French.

PMID:
11413853
19.

Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature.

Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM.

J Int Assoc Physicians AIDS Care (Chic). 2009 Mar-Apr;8(2):113-21. doi: 10.1177/1545109709332019. Epub 2009 Mar 6. Review.

PMID:
19270151
20.

[Patient-related cardiovascular risk factors in the HIV-infected population].

Portilla J.

Enferm Infecc Microbiol Clin. 2009 Sep;27 Suppl 1:10-6. doi: 10.1016/S0213-005X(09)73440-8. Review. Spanish.

PMID:
20172410
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk